Skip to main content
KANGSTEM BIOTECH CO., LTD. logo

KANGSTEM BIOTECH CO., LTD. — Investor Relations & Filings

Ticker · 217730 ISIN · KR7217730001 KO Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2019-03-26 Capital/Financing Update
Country KR South Korea
Listing KO 217730

About KANGSTEM BIOTECH CO., LTD.

https://kangstem.com

KANGSTEM BIOTECH CO., LTD. is a biopharmaceutical company that researches and develops advanced stem cell therapies. The company focuses on creating treatments for rare, incurable, and autoimmune diseases, with a pipeline that includes therapeutic candidates for neurological disorders. Leveraging proprietary technologies for the isolation and mass culture of mesenchymal stem cells, Kangstem Biotech also develops and commercializes stem cell culture media and related cosmetic products. The company is dedicated to addressing unmet medical needs through the development of next-generation biopharmaceuticals.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(제대혈 유래 줄기세포 아토피피부염 치료제 국내 독점판권/통상실시권 설정 및 기술전수 계약 체결)
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from the Korea Exchange (KRX) system (KIND) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details a specific business contract (licensing and technology transfer agreement) between Kangstem Biotech and SK Bioland. Since this is a specific corporate announcement regarding a material business event that does not fit into categories like M&A, dividends, or financial reports, it is classified as a general regulatory filing.
2019-03-26 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of a General Meeting of Shareholders (AGM) for Kangstem Biotech. It details the outcomes of various agenda items, including the approval of financial statements, election of directors, and remuneration limits. Since it provides the official results of the shareholder votes conducted during the meeting, it falls under the category of Declaration of Voting Results.
2019-03-21 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options). It details the issuance of stock options to specific employees, including the exercise price, vesting period, and valuation methodology. In the context of Korean financial regulations (DART system), this is a specific disclosure regarding capital/equity-related changes. Since it does not fit into the specific categories of 'Share Issue' (SHA) or 'Director's Dealing' (DIRS) perfectly, and is a standard regulatory disclosure for stock option grants, it is classified as a Regulatory Filing (RNS).
2019-03-21 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) submitted to the Korea Exchange (KRX). It contains key financial data, audit opinions, and financial statements for the fiscal year. While it provides financial information, it is a standard regulatory disclosure form used by Korean companies to announce the receipt and submission of the audit report to the regulator, rather than the full annual report document itself. Therefore, it is classified as a Regulatory Filing (RNS). FY 2018
2019-03-13 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Kangstem Biotech. It outlines the date, location, and agenda items (such as approval of financial statements, election of directors, and remuneration limits). This type of document is a standard proxy solicitation or notice of meeting sent to shareholders to inform them of upcoming voting matters, which falls under the Proxy Solicitation & Information Statement category.
2019-03-05 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Kangstem Biotech. It contains the meeting agenda, details on board elections, financial statements for approval, and management reports. While it includes financial data, it is primarily a proxy statement/notice for shareholders to attend the meeting and vote on specific items. In the context of financial filings, this is classified as a Proxy Solicitation & Information Statement (PSI).
2019-03-05 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.